Shemesh-Iron M, et al. - In this 4-year intervention study (1-year double-blinded, randomized, placebo-controlled [growth hormone (GH)/placebo-2:1] and 3-year open-labeled GH therapy), authors estimated the consequence of GH therapy on psychosocial well-being and also to ascertain the ability of psychological metrics to define short stature-related distress. They found lower Pediatric Quality of Life Inventory (PedsQL) of boys with idiopathic short stature as compared to Pediatric Quality of Life Inventory (PedsQL) of boys with idiopathic short stature at study entry. Improvement in actual and anticipated adult height perception (SAT, P) with reduced short stature-related distress (SC-IAT-H) was noticed in GH-treated boys after the 1-year blinded intervention. They concluded a significant improvement in height perception and self-esteem with long-term open-labeled GH treatment.